ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524

Drugs in R and D

Volumn 8, Issue 2, 2007, Pages 103-112

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; ISA 247; LX 211; PLACEBO; R 1524; TACROLIMUS; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTHRITIS; AUTOIMMUNE DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DIARRHEA; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG STRUCTURE; GRAFT REJECTION; HEADACHE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; UVEITIS;

ANIMALS; CALCINEURIN; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; CYCLOSPORINE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; RABBITS; RANDOMIZED CONTROLLED TRIALS; SKIN DISEASES;

EID: 33847395950     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200708020-00005     Document Type: Review

References (36)

1. Isotechnika Inc. Isotechnika Earns Significant Drug Development Milestone Payment. Media Release: 26 Sep 2002. Available from URL: http://www. isotechnika.com
2. Isotechnika Inc, Roche Pharmaceutical Division. Isotechnika and Roche sign largest drug development agreement in Canadian history. Media Release: 9 Apr 2002. Available from URL: http://www.isotechnika.com
3. Isotechnika Inc. Isotechnika Signs Option Agreement for Topical Delivery Technology of ISA247. Media Release: 25 Apr 2006. Available from URL: http://www.isotechnika.com
4. Isotechnika Inc, Atrium Medical Corporation. Isotechnika and Atrium Medical Announce Licensing Agreement for Use of TAFA93 and ISA247 With Medical Devices. Media Release: 30 Sep 2005. Available from URL: http://www.isotechnika. com
5. Isotechnika Inc. Isotechnika signs agreement granting Lux Biosciences Worldwide Ophthalmic rights to ISA247. Media Release: 25 May 2006. Available from URL: http://www.isotechnika.com
6. Isotechnika Inc. Isotechnika Announces Interim Blinded Phase III Psoriasis Results. Media Release: 3 Aug 2005. Available from URL: http://www.isotechnika.com
7. Isotechnika Inc. Isotechnika Inc. announces highlights and financial results for first quarter of 2006. Media Release: 15 May 2006. Available from URL: http://www.isotechnika.com
8. Isotechnika Inc. Isotechnika Inc. Announces Fourth Quarter and Year End Financial Results. Media Release: 11 Mar 2003. Available from URL: http://www.isotechnika.com
9. Isotechnika Inc. Isotechnika and Roche Announce Completion of Patient Recruitment for ISA247 Phase II A Clinical Trial in Kidney Transplantation. Media Release: 3 Oct 2002. Available from URL: http://www.isotechnika.com
10. Isotechnika Inc. Isotechnika Inc. Achieves all Endpoints in Multiple Ascending Dose Study for ISA247. Media Release: 3 Nov 2004. Available from URL: http://www.isotechnika.com
11. Isotechnika Inc. Isotechnika Inc. Reports Interim Results of QTc Trial. Media Release: 9 Sep 2004. Available from URL: http://www.isotechnika.com
12. Isotechnika Inc. Positive Data From Trans-ISA247 Single Ascending Dose Trial. Media Release: 6 Jul 2004. Available from URL: http://www.isotechnika.com
13. Isotechnika Inc. FDA Agrees to Clinical Development Plans for ISA247. Media Release: 25 Feb 2004. Available from URL: http://www.isotechnika.com
14. Isotechnika Inc. Isotechnika Receives European Patent for Lead Immunosuppressive Drug, ISA247. Media Release: 3 Oct 2006. Available from URL: http://www.isotechnika.com
15. Isotechnika Inc. Isotechnika receives additional U.S. patent for lead immunosuppressive drug, ISA247 - 30 June 2006. Media Release: 30 Jun 2006. Available from URL: http://www.isotechnika.com
16. Isotechnika Inc. Isotechnika receives additional U.S. patent for lead immunosuppressive drug, ISA247. Media Release: 14 Feb 2006. Available from URL: http://www.isotechnika.com
17. Yatscoff RW, Abel MD, Aspeslet LJ, et al. ISA(TX)247: phase 1 clinical trial results of the novel calcineurin inhibitor. Journal of Rheumatology 28 (Suppl. 63): 109, Jul 2001
18. Wasel NR, Gupta A, Tomi Z, et al. Pharmacokinetics and pharmacodynamics of ISA247 in a phase III, randomized, multicenter, double-blind, placebo-controlled study. Journal of the American Academy of Dermatology 54 (Suppl. 1): AB9 (plus poster) abstr. P36, No. 3, Mar 2006
19. Yatscoff RW, Abel MD, Aspeslet LJ, et al. A novel calcineurin inhibitor with minimal renal toxicity: ISA(TX)247. Journal of Rheumatology 28 (Suppl. 63): 109, Jul 2001
20. Isotechnika Inc. Isotechnika Presents Interim Clinical Data at the International Congress of the Transplantation Society. Media Release: 29 Aug 2002. Available from URL: http://www.isotechnika.com
21. Yatscoff RW, Abel MD, Aspeslet LJ, et al. Phase 2, randomized, multicenter, open-label study of ISA247 and Neoral (Rm) in post-renal transplant patients. American Journal of Transplantation 3 (Suppl. 5): 463 (plus oral presentation) abstr. 1215, 2003
22. Papp K, Bissonnette R, Langley R, et al. A phase III randomized multicentre, double-blind, placebo-controlled study of ISA247 in plaque psoriasis patients: an interim report. 80th Annual Conference of the Canadian Dermatology Association: [1 page], 28 Jun 2005. Available from: URL: http://www.isotechnika.com
23. Isotechnika Inc. Isotechnika Inc. announces highlights and financial results for first quarter. Media Release: 13 May 2005. Available from URL: http://www.isotechnika.com
24. Papp K, Langley R, Bissonnette R, et al. A phase III, randomized, multicenter, double-blind, placebo-controlled study of ISA247 in plaque psoriasis patients. Journal of the American Academy of Dermatology 54 (Suppl. 1): AB9 (plus poster) abstr. P33, No. 3, Mar 2006
25. Isotechnika Inc. Isotechnika's Phase III Psoriasis Trial Achieves Clinical Endpoints. Media Release: 21 Sep 2005. Available from URL: http://www.isotechnika.com
26. Isotechnika Inc. Isotechnika's Phase III Psoriasis Spirit Trial Achieves Safety and Efficacy Endpoints. Media Release: 7 Nov 2005. Available from URL: http://www.isotechnika.com
27. Isotechnika Inc. Isotechnika Announces Nine Month Safety Data From the Phase III Psoriasis Trial for ISA247. Media Release: 8 Dec 2005. Available from URL: http://www.isotechnika.com
28. Isotechnika Inc. Isotechnika announces preliminary 48 week clinical data from the Phase III ISA247 psoriasis trial. Media Release: 20 Mar 2006. Available from URL: http://www.isotechnika.com
29. Gregory CR, Kyles AE, Bernsteen L, et al. Compared with cyclosporine, ISA(TX)247 significantly prolongs renal-allograft survival in a northern prmate model. Transplantation 78: 681-685, No. 5, 15 Sep 2004
30. Mayo P, Freitag D, Boutouyrie-Dumont B, et al. Pharmacokinetics and pharmacodynamics of ISA247 a new generation calcineurin inhibitor in stable renal transplant patients. American Journal of Transplantation 4 (Suppl. 8): 490, May 2004
31. Isotechnika Inc. Isotechnika to Present at International Dermatology Conference. Media Release: 3 Dec 2002. Available from URL: http://isotechnika. com
32. Isotechnika Inc. Isotechnika and Roche Announce Completion of Patient Recruitment for ISA(TX)247 Phase II Clinical Trial in Psoriasis. Media Release: 26 Jun 2002. Available from URL: http://www.isotechnika.com
33. Isotechnika Inc. Isotechnika's Phase II Clinical Trial of ISA247 in Patients With Psoriasis Yields Impressive Results. Media Release: 10 Mar 2003. Available from URL: http://www.isotechnika.com
34. Lynde C, Kunynetz R, Guenther L, et al. A phase III, randomized, multicenter, double-blind, placebo-controlled, quality of life study of ISA247 in plaque psoriasis patients. Journal of the American Academy of Dermatology 54 (Suppl. 1): AB210 (plus poster) abstr. P2851, No. 3, Mar 2006
35. Isotechnika Inc. Isotechnika Announces Initial Data From Phase IIb Kidney Transplant Trial. Media Release: 16 Nov 2006. Available from URL: http://www.isotechnika.com
36. Isotechnika Inc. Isotechnika Releases Final Results of Phase IIa Kidney Transplant Trial at American Transplant Congress. Media Release: 4 Jun 2003. Available from URL: http://www.isotechnika.com